

Grifols reports a 23.7% increase in sales in the first nine months of 2006

- **Turnover through September 2006 reached 482 million euros and the net profit grew 5.2%, or 28.4 million euros**

Barcelona, November 6 2006: Grifols, a holding company specialized in the pharmaceutical-hospital sector and fourth in the world in plasma derivatives manufacturing has attained an accumulated net profit of 28.4 million euros in the first nine months of this fiscal year, 5.2% greater than the same period last year. Improved operating margins and healthy growth in sales, principally in the United States, has fuelled the company's net profits to reach 12.4 million euros in the third quarter alone, compared to the 6 million euros attained in July and September of 2005.

Moreover, the net profit accumulated through September 2006 includes one-off impacts from the repurchase and amortization of non-voting shares cancelled in May 2006, which affected first quarter results to the value of 21.9 million euros. Were it not for the impact of the amortization of these shares, net profit would have been over 41%.

The profit attained reflects the growth in the group's net sales in the first 9 months of 2006 to reach 482 million euros, 23.7% more than in the same period last year. In the third quarter alone, turnover grew 23.6% and reached 160 million euros.

The **Bioscience** division continues to be the best performer, with a turnover of 329 million euros, increasing 21.7%. Sales from this line of business, the driving force of the holding company, were due mainly to an increase in the amount of Factor VIII sold and the rise in prices of albumin and IGIV (immunoglobulin intravenous) in the United States.

The **Diagnostic** division continues its rate of growth with a turnover of more than 55 million euros, which represents an increase of 8.8% compared to the first nine months of 2005. Sales in diagnostic equipment and reagents, especially DG Gel cards, has been especially significant. In order to meet growing demand, Grifols has initiated the expansion of the Diagnostic plant in Parets del Valles (Barcelona), which will triple the production of gel cards and grow its presence in the global immunohematology market. The investment totaled 2.3 million euros, with construction scheduled to finish in the second quarter of 2007.

Finally, the **Hospital** division has grown 8.6%, with business turnover reaching 46.2 million euros. In the third quarter of this year, a third manufacturing line for the filling of large volume bags (3 liters) has been put into operation at the parenteral solutions plant in Parets del Valles (Barcelona). The **Raw Materials** division doubled its turnover to reach 50.8 million euros compared to the same period in 2005. This division includes the sales of intermediary products and primary materials (plasma) to third parties, the latter being a result of contracts existing before the recent acquisition of PlasmaCare in early 2006.

- **Grifols strengthens its position in the United States and opens a representation office in Japan**

The results obtained in the first 9 months of 2006 reflect Grifols' international strategy, specifically in the US market, which currently accounts for 36.7% of the group's sales. Turnover in the US alone rose to 157.4 million euros, compared to 108 million recorded in the same period in 2005 (using a comparable figure which excludes the sales generated from the recently acquired PlasmaCare).

Additionally, the holding company intends to consolidate its position through expansion and the construction of new plants in its industrial complex in Los Angeles. Investments will rise to 12 million euros and will allow Grifols to improve processes used in the purification and sterile doping processes for coagulation factors (plasma derivatives). In the second phase, the plant will incorporate the sterile dosing of albumin.

In terms of the company's international strategy, in the third quarter Grifols has opened a representation office in Japan in order to help plan the introduction of the company's products in this marketplace over the next 3 to 5 years. Grifols already sells diagnostic instruments in Japan with a turnover of 1.3 million euros in 2005.

Grifols figures from the first nine months of 2006

	30.09.06 (Millions €)	% 06 - 05
BY GEOGRAPHIC AREA		
Europe	251.2	6.9%
USA	177.2	63.9%
Other areas (Asia, etc.)	53.8	15.8%
Total:	482.2	23.7%
BY DIVISIONS		
Bioscience	329.3	21.7%
Diagnostic	55.9	8.8%
Hospital	46.2	8.6%
Raw Materials	50.8	101.7%
Total:	482.2	23.7%